The New York Times.Next
In March, El Salvador received 1 million doses of a total 2 million dose order for CoronaVac.
Retrieved 10 January 2021. It is best if the risk of side effects is minimal with vaccines and that any effects are mild.Next
Retrieved 21 May 2021.
The previous record-holder, the mumps vaccine, took more than four times as long to see the light of day. The Lancet Infectious Diseases.
On 10 December, São Paulo Governor João Doria said that in the interim, prior to the local manufacture of CoronaVac, Instituto Butantan aimed to 1 million doses of the vaccine per day.
Retrieved 6 February 2021. Retrieved 5 August 2021. Retrieved 27 April 2021.
Content is fact checked after it has been edited and before publication.
The vaccine prevented hospitalization and severe illness in 100% of cases, with all six people who were hospitalized in the placebo group. Distribution of the locally produced vaccine will begin by August and it will be used locally and sent to other African nations.
Retrieved 30 July 2021.
What is Sinovac Vaccine? A total of 12,396 volunteers participated in the study between 21 July and 16 December 2020. Effectiveness In Brazil, a study was conducted in , population 45,000, where authorities attempted to vaccinate the entire adult population with CoronaVac. A political showdown began in October 2020, when Bolsonaro vetoed a deal between the Brazilian health ministry and the São Paulo government for the purchase of 46 million doses of the vaccine.Next
Retrieved 15 April 2021.
The vast majority of those infected were protected from severe symptoms and recovered without hospitalization. Retrieved 11 November 2021. Retrieved 29 March 2021.Next
Variability in results In early January 2021, Brazilian health officials announced that the vaccine had an efficacy of 78%.
The vaccination campaign with CoronaVac began on 26 February.
The WHO expressed high level of confidence in the efficacy of the vaccine for adults, moderate confidence in the efficacy for older adults and individuals with comorbidities, moderate confidence in its safety for adults and low confidence in its safety for the elderly and individuals with comorbidities.